loader2
Partner With Us NRI

Nectar Lifescience Ltd share Price Today

Company details

33.10
34.15
16.50
45.70
6M Return 7.75%
1Y Return 99.10%
Mkt Cap.(Cr) 747.91
Volume 190,249
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 190,249

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Nectar Lifescience Ltd shares SWOT Analysis

Strengths (6)

  • Rising Net Cash Flow and Cash from Operating activity
  • Strong Annual EPS Growth
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Weakness (1)

  • Companies with High Promoter Pledge

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (2)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 34.0
R2 34.6
R3 35.0
Pivot

33.53

S1 32.9
S2 32.5
S3 31.9
EMA SMA
34.0
34.1
33.4
30.9
34.2
33.6
34.9
30.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ANKITA VISHAL SHAH Bulk Purchase 2024-02-16 43.88 1547355 NSE
CITADEL SECURITIES INDIA MARKETS PRIVATE LIMITED Bulk Purchase 2024-02-16 41.52 1168957 NSE
ANKITA VISHAL SHAH Bulk Sell 2024-02-16 43.34 1097355 NSE
Name Category Shares
SANJIV GOYAL PROMOTER 31.33%
SANJIV (HUF) PROMOTER 24.47%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Nectar Lifescience Ltd Stocks COMPARISON

Financials( in Cr) Nectar Lifescience Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 33.35 1,495.10 1,489.15 1,086.05 4,113.00
% Change 0 -2.87 0.46 0.50 1.34
Mcap Cr 747.91 358,724.58 120,229.06 109,282.04 109,187.40
Revenue TTM Cr 1,523.67 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr -24.18 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 151.18 35.84 28.23 28.33 78.90
1 Year Return 99.10 60.49 60.05 114.02 21.48
ROCE -0.18 16.79 14.76 16.25 19.30
ROE -6.01 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,064.60 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 39,612.39 -26,051.38
LAST 3M 102,786.44 -35,737.56
LAST 6M 169,824.52 46,518.61
LAST 12M 263,183.06 125,165.94

Nectar Lifescience Ltd Information

Stock PE (TTM)
151.18
Promoter Holding
44.35%
Book Value
47.6787
ROCE
-0.18%
ROE
-6.01%
Description
  • Nectar Lifesciences Ltd (NLL or NECLIFE) is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. The company manufactures Cephalosporin Active pharmaceutical ingredients, finished dosage forms, Phytochemicals, and hard gelatin capsules at their facilities spread across three Indian states of Punjab, Himachal Pradesh and Jammu. They have developed sustainable production systems to manufacture high quality intermediates and APIs to meet the diverse requirements of their customer base in India and over 90 countries worldwide. The company`s business operations are primarily concentrated on manufacturing and marketing of oral and sterile cephalosporins, phytochemicals and allied products. They manufacture and sell a range of cephalosporins and phytochemicals. They are also engaged in contract manufacturing of API`s for pharmaceutical players. Nectar Lifesciences Ltd was incorporated on June 27, 1995 as a public limited company with the name Surya Medicare Ltd. The company was established pursuant to a financial collaboration agreement between the Promoters and Punjab State Industrial Development Corporation. In April 1997, the company commenced business with the commercial production of Oral Bulk Drugs at their manufacturing facility located in the B Category zone of Punjab. In March 1998, they started the production of Sterile Bulk Drugs. In the year 1999, they added the formulation facilities by setting up a vial filing section for Crystalline Sterile Bulk Drugs. In the year 2000, the company undertook an expansion by increasing the installed capacity Crystalline Sterile Bulk Drugs from 406 MT to 810 MT. In the year 2001, they also installed one Crystalline section of 65 MT per annum, which commenced production in October 2001. In the year 2002, the company undertook another expansion programme increasing the production capacity for Cephalosporin Sterile. In October 18, 2002, they incorporated Chempharma (Pvt) Ltd as a wholly-owned subsidiary company in Sri Lanka to manufacture API intermediaries. In the year 2003, the company commenced modernization / expansion plan for increasing our presence in the Cephalosporins segment. In April 2003, the company bought back the entire shareholding of PSIDC at a price of Rs 16.47 per share under the One Time Settlement policy announced by Government of Punjab - Industrial Policy, 2003. In the year 2004, the company started production in a portion of the new Cephalosporins plant. In March 26, 2004, the company changed their name from Surya Medicare Ltd to Nectar Lifesciences Ltd. During the year 2006-07, the company commissioned a state-of-the-art facility dedicated to the non-antibiotic therapeutic segment in compliance with stringent US-FDA and EDQM guidelines. The company established a state-of-the-art mint derivatives plant, initiating its business activity into the phytochemicals arena. They also up a menthol flakes facilities at SIDCO Industrial Complex, Jammu to add to the requisite business activity with all the locational benefits to the industry in J&K. They commissioned a unit in Derabassi to process menthol into powder and crystal forms The company also established an Empty Hard Gelatin Capsule unit at Baddi, Himachal Pradesh referred to as Unit VII which commenced production with effect from April 2007. In April 2008, they set up a state-of-the-art facility, Unit X at Derabassi, which commissioned on April 17, 2008. During the year 2008-09, the company increased the production capacity of Bulk Drug & Sterile from 425 MT to 650 MT. Also, they increased the production capacity of Phytochemicals - Menthol from 6000 MT to 7600 MT. They launched 30 formulation brands (P2P). Also, they established a fully-owned formulation R&D centre in Derabassi dedicated to non-cephalosporins related developments like oncology, anti-diabetes, cardiovascular system, female healthcare and anti-HIV. During the year 2009-10, the company increased the production capacity of Bulk Drug & Sterile from 650 MT to 1600 MT. Also, they launched the diagnostic division during the year. During FY 2010-11, M/s Nectar Capital Limited was incorporated in Mauritius and M/s Nectar Lifesciences UK Limited, was incorporated in United Kingdom. Nectar Lifesciences US, LLC in United States was also incorporated during year 2014-15, which commenced the business operations of trading in pharmeceutical products. In March 2011, the company received approval from the Japanese MOH for their product, Cefuroxime Axetil. The company incorporated a WOS namely NECLIFE PT, UNIPESSOAL LDA in Portugal on July 11, 2019 to takeover MA from Nectar Lifesciences UK Limited. Two new innovative products in EHGC - menthol capsules (Nexxicap MintyTM) and pearl capsule (Nexxicap PearlTM) were launched in 2019-20.

Registered Address

Village Saidpura, Tehsil Derabassi S A S Nagar, Mohali, Punjab, 140507

Tel : 91-1762-308000
Email : cs:neclife.com
Website : http://www.neclife.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532649
NSE Code : NECLIFE
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE023H01027

FAQ’s on Nectar Lifescience Ltd Shares

You can buy Nectar Lifescience Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Nectar Lifescience Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 23, 2024 03:47 PM the closing price of Nectar Lifescience Ltd was Rs.33.35.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 23, 2024 03:47 PM, the market cap of Nectar Lifescience Ltd stood at Rs. 747.91.

The latest PE ratio of Nectar Lifescience Ltd as of May 23, 2024 03:47 PM is 151.18

The latest PB ratio of Nectar Lifescience Ltd as of May 23, 2024 03:47 PM is 1.43

The 52-week high of Nectar Lifescience Ltd share price is Rs. 45.70 while the 52-week low is Rs. 16.50

Download App

Download Our App

Play Store App Store
market app